MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.77
+0.01
+0.17%
Opening 11:14 10/19 EDT
OPEN
5.80
PREV CLOSE
5.76
HIGH
5.90
LOW
5.77
VOLUME
11.70K
TURNOVER
--
52 WEEK HIGH
9.74
52 WEEK LOW
2.470
MARKET CAP
66.44M
P/E (TTM)
-4.8639
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kazia executes agreement to initiate pivotal study in a form of brain cancer
Kazia Therapeutics ([[KZIA]]) has executed an agreement with the Global Coalition for Adaptive Research ((GCAR)) to begin participation in the GBM AGILE pivotal study in glioblastoma.The study is set to
Seekingalpha · 2d ago
Kazia Executes Agreement To Commence GBM Agile Pivotal Study Of Paxalisib As A Treatment For Glioblastoma, Recruitment Expected To Begin In Q1 2021
SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement
Benzinga · 3d ago
Kazia Executes Agreement To Commence GBM Agile Pivotal Study
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participation in the GBM AGILE pivotal study in glioblastoma. The study will open a new arm with Kazia's investigational new drug, paxalisib (formerly GDC-0084), and will now move into an operational phase with recruitment of patients to the paxalisib arm expected to begin in Q1 CY2021.
PR Newswire · 3d ago
Kazia inks clinical pact with Dana-farber Cancer Institute for its lead asset in primary CNS lymphoma
Kazia Therapeutics ([[KZIA]] +0.9%) has collaborated with Dana-Farber Cancer Institute ((DFCI)), to investigate its lead drug, paxalisib (formerly GDC-0084), in primary central nervous system ((PCNSL)) lymphoma, a potential new indication for
Seekingalpha · 09/22 15:35
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to investigate the use of Kazia's investigational new drug, paxalisib
PR Newswire · 09/22 02:21
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
LONDON, UK / ACCESSWIRE / September 2, 2020 / We are reinitiating on Kazia Therapeutics (NASDAQ:KZIA), which is entering late-stage trials for its lead product, paxalisib, for glioblastoma multiforme (GBM).
ACCESSWIRE · 09/02 14:15
We're Hopeful That Kazia Therapeutics (ASX:KZA) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Kazia Therapeutics...
Simply Wall St. · 09/01 06:23
5 Stocks To Watch For August 24, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 08/24 10:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZIA. Analyze the recent business situations of Kazia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 11
Institutional Holdings: 986.60K
% Owned: 8.57%
Shares Outstanding: 11.51M
TypeInstitutionsShares
Increased
2
57.24K
New
0
0
Decreased
1
8.56K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.62%
Pharmaceuticals & Medical Research
-0.49%
Key Executives
Non-Executive Chairman
Iain Ross
Chief Executive Officer/Executive Director
James Garner
Other
Gordon Hirsch
Other
Lilischkis Kimberley
Other
Peng Leong
Other
Stephen Palmer
Other
Justine Stehn
Secretary
Kate Hill
Non-Executive Director
Bryce Carmine
Non-Executive Director
Steven Coffey
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KZIA
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kazia Therapeutics Ltd (ADR) stock information, including NASDAQ:KZIA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZIA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZIA stock methods without spending real money on the virtual paper trading platform.